HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer

Volume: 162, Issue: 10
Published: Jul 28, 2021
Abstract
The lethality of estrogen receptor alpha positive (ER+) breast cancer, which is often considered to have better prognosis than other subtypes, is defined by resistance to the standard of care endocrine treatment. Relapse and metastasis are inevitable in almost every patient whose cancer is resistant to endocrine treatment. Therefore, understanding the underlying causes of treatment resistance remains an important biological and clinical focus of...
Paper Details
Title
HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer
Published Date
Jul 28, 2021
Volume
162
Issue
10
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.